Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Phase 4

Completed

Conditions: Heart Failure and Reduced Ejection Fraction

Interventions: Drug: LCZ696 (sacubitril/valsartan)
Drug: Enalapril
Drug: Placebo of Enalapril
Drug: Placebo of LCZ696

First Posted Date: 2016-08-22

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 465

Registration Number: NCT02874794

Locations: 🇺🇸
Novartis Investigative Site, Manitowoc, Wisconsin, United States

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

Phase 1

Terminated

Conditions: Hepatic Impairment

Interventions: Drug: dabrafenib

First Posted Date: 2016-08-19

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT02873650

Locations: 🇺🇸
American Institute of Research, Los Angeles, California, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸
Wake Research Associates Oncology, Raleigh, North Carolina, United States

and more 1 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Phase 1

Completed

Conditions: Macular Edema
Retinal Vein Occlusions
Diabetic Macular Edema
Neovascular Age-related Macular Degeneration

Interventions: Drug: LKA651
Other: Sham Comparator

First Posted Date: 2016-08-16

Last Posted Date: 2022-04-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT02867735

Locations: 🇵🇷
Novartis Investigative Site, Arecibo, Puerto Rico

SCHEDULE Follow Up Visit 5-7 yr

Phase 4

Completed

Conditions: Heart Transplantation

Interventions: Drug: Everolimus
Drug: Cyclosporine
Drug: Mycophenolate mofetil
Drug: Corticosteroids

First Posted Date: 2016-08-12

Last Posted Date: 2019-10-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT02864706

Locations: 🇸🇪
Novartis Investigative Site, Lund, Sweden

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: ABL001

First Posted Date: 2016-08-05

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT02857868

Locations: 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
University of Miami / Clinical Research Services, Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: Tropifexor (LJN452)
Drug: Placebo

First Posted Date: 2016-08-04

Last Posted Date: 2021-09-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 350

Registration Number: NCT02855164

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: dabrafenib

First Posted Date: 2016-08-02

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 22

Registration Number: NCT02852239

Locations: 🇺🇸
Omega Research Consultants LLC, DeBary, Florida, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸
Wake Research Associates Oncology, Raleigh, North Carolina, United States

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Phase 4

Completed

Conditions: Pancreatic Neuroendocrine Tumors

Interventions: Drug: everolimus

First Posted Date: 2016-07-25

Last Posted Date: 2025-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 61

Registration Number: NCT02842749

Locations: 🇨🇳
Novartis Investigative Site, Shanghai, China

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: BLZ945
Drug: PDR001

First Posted Date: 2016-07-12

Last Posted Date: 2024-01-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 192

Registration Number: NCT02829723

Locations: 🇺🇸
Dana Farber Cancer Institute Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan
🇺🇸
Sarah Cannon Research Institute Sarah Cannon Research, Nashville, Tennessee, United States

and more 2 locations

A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: IDH305

First Posted Date: 2016-07-11

Last Posted Date: 2019-04-10

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02826642

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy